Madrigal Pharmaceuticals price target raised to $533 from $431 at Clear Street

Clear Street raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $533 from $431 and keeps a Buy rating on the shares to reflect Rezdiffra’s continued strong performance, even as Wegovy enters the F2-F3 MASH market. As a result of Rezdiffra’s sustained growth, the firm has increased its peak penetration assumption to 20% from 15% for F2-F3 MASH, the analyst noted.